Plasma adrenomedullin and obstructive sleep apnea

• Published in: American journal of hypertension Vol. 17; no. 1; pp. 74 - 76
• Main Authors: Wolk, Robert, Svatikova, Anna, Otto, Maria E, Hoffmann, Michal S, Duenwald, Carolyn J, Somers, Virend K
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 2004; Oxford University Press; Elsevier Science
• Subjects: Adrenomedullin; Adult; Arterial hypertension. Arterial hypotension; Biological and medical sciences; Blood and lymphatic vessels; Body Mass Index; Cardiology. Vascular system; Continuous Positive Airway Pressure; Humans; Hypertension - blood; Hypertension - complications; Hypertension - therapy; Male; Medical sciences; Middle Aged; Peptides - blood; Polysomnography; sleep apnea; Sleep Apnea, Obstructive - blood; Sleep Apnea, Obstructive - complications; Sleep Apnea, Obstructive - therapy; Adrenomedullin; sleep apnea; continuous positive airway pressure; Hypertension; Apnea; Sleep; Positive pressure; Cardiovascular disease; Sleep wake cycle
• ISSN: 0895-7061; 1879-1905; 1941-7225
• DOI: 10.1016/j.amjhyper.2003.09.004

Obstructive sleep apnea (OSA) is associated with hypertension. The vasorelaxing peptide adrenomedullin (ADM) may counteract effects of OSA-induced release of vasopressor substances.
Plasma ADM levels were measured at 9:30
pm, 2:00
am (after 4 to 5 h of untreated OSA), and 6:00
am (after 4 h of continuous positive airway pressure treatment) in 15 OSA patients and in 10 controls.
Baseline ADM levels were similar in the OSA and control groups (28.7 ± 6.7
v 27.7 ± 6.4 pg/mL, respectively), did not change overnight in either group, and were not affected by continuous positive airway pressure.
OSA does not exert any significant acute or chronic effects on plasma ADM levels.